Staar Surgical (NSDQ:STAA) posted third-quarter results after markets closed yesterday that beat the consensus forecast on Wall Street and raised its outlook for the rest of the year.
The Lake Forest, California-based implantable lens maker reported profits of $6.0 million, or $0.12 per diluted share, on sales of $58.4 million for the three months ended Oct. 1, for a bottom-line gain of 55% and sales growth of 23.9% compared with Q3 2020.
STAAR Surgical President and CEO Caren Mason said Implantable Collamer Lens (ICL) orders exceeded inventory in the quarter.